Sabrina Law
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sabrina Law has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Shezad
The Heart Institute, Cincinnati Children's Hospital Medical Center
5 shared publications - Anna Joong
Lurie Children's Hospital of Chicago
4 shared publications Shahnawaz Amdani
Department of Pediatric Cardiology, Cleveland Clinic Children's, Cleveland, Ohio
4 shared publications- Aamir Jeewa
Labatt Family Heart Centre, Division of Pediatric Cardiology, Department of Pediatrics, University of Toronto, Hospital for Sick Children, Toronto, Canada
3 shared publications David M. Peng
Division of Pediatric Cardiology, C.S. Mott Children's Hospital, Ann Arbor, Michigan
3 shared publications- David W. Bearl
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, USA
3 shared publications
Latest Publications
- 18 September 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (9)
Donor‐Recipient Size Mismatch, Age at Transplant, and Elevated Donor‐Derived Cell‐Free DNA % Early After Pediatric Heart Transplant
Background: Acute rejection (AR) is a major cause of graft loss after orthotopic heart transplant (OHT). Donor‐derived cell‐free DNA fraction (dd‐cfDNA%) is a noninvasive biomarker for AR but may be elevated without AR. We evaluated associations of donor‐recipient size mismatch and recipient age with early dd‐cfDNA% in pediatric OHT recipients without AR. Methods: This single‐center retrospective study evaluated initial dd‐cfDNA% testing in pediatric OHT recipients without AR. Size mismatch was assessed using donor‐to‐recipient body surface area (BSA) ratio, weight ratio, and allograft left ventricular (LV) mass z‐score. Associations with dd‐cfDNA% were assessed using Spearman correlation and Mann–Whitney U tests; multivariable linear regression adjusted for age. Analyses of size mismatch and recipient age were repeated at the second post‐OHT dd‐cfDNA assessment. Results: Between 2022 and 2025, 58 pediatric OHT recipients underwent dd‐cfDNA% testing; 39 had no rejection. After excluding 2 outliers, 37 remained. Higher first dd‐cfDNA% was associated with larger BSA ratio ( p = 0.039), BSA ratio ≥ 1.5 (median 0.17% vs. 0.06%, p = 0.0185), larger weight ratio ( p = 0.016), LV mass oversizing (median 0.17% vs. 0.06%, p = 0.0196), and younger age ( p = 0.008). After age adjustment, neither size mismatch nor age was independently associated with first dd‐cfDNA%. No significant associations were observed at the second assessment. Conclusions: Greater donor‐recipient size mismatch and younger recipient age were associated with higher first dd‐cfDNA% in unadjusted analyses, but not after age adjustment. These exploratory findings support further investigation of size mismatch, recipient age, and early allograft adaptation as potential non‐rejection contributors to dd‐cfDNA elevation.
- 18 September 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (9)
Donor‐Recipient Size Mismatch, Age at Transplant, and Elevated Donor‐Derived Cell‐Free DNA % Early After Pediatric Heart Transplant
Background: Acute rejection (AR) is a major cause of graft loss after orthotopic heart transplant (OHT). Donor‐derived cell‐free DNA fraction (dd‐cfDNA%) is a noninvasive biomarker for AR but may be elevated without AR. We evaluated associations of donor‐recipient size mismatch and recipient age with early dd‐cfDNA% in pediatric OHT recipients without AR. Methods: This single‐center retrospective study evaluated initial dd‐cfDNA% testing in pediatric OHT recipients without AR. Size mismatch was assessed using donor‐to‐recipient body surface area (BSA) ratio, weight ratio, and allograft left ventricular (LV) mass z‐score. Associations with dd‐cfDNA% were assessed using Spearman correlation and Mann–Whitney U tests; multivariable linear regression adjusted for age. Analyses of size mismatch and recipient age were repeated at the second post‐OHT dd‐cfDNA assessment. Results: Between 2022 and 2025, 58 pediatric OHT recipients underwent dd‐cfDNA% testing; 39 had no rejection. After excluding 2 outliers, 37 remained. Higher first dd‐cfDNA% was associated with larger BSA ratio ( p = 0.039), BSA ratio ≥ 1.5 (median 0.17% vs. 0.06%, p = 0.0185), larger weight ratio ( p = 0.016), LV mass oversizing (median 0.17% vs. 0.06%, p = 0.0196), and younger age ( p = 0.008). After age adjustment, neither size mismatch nor age was independently associated with first dd‐cfDNA%. No significant associations were observed at the second assessment. Conclusions: Greater donor‐recipient size mismatch and younger recipient age were associated with higher first dd‐cfDNA% in unadjusted analyses, but not after age adjustment. These exploratory findings support further investigation of size mismatch, recipient age, and early allograft adaptation as potential non‐rejection contributors to dd‐cfDNA elevation.
- 10 June 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (10) , 1668-1671
Multi-institutional outcomes of Impella use in pediatric patients: A brief communication from the ACTION Network
- 10 June 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (10) , 1668-1671
Multi-institutional outcomes of Impella use in pediatric patients: A brief communication from the ACTION Network
- 18 January 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 530-540
The ACTION VAD registry: A collective five-year experience
- 18 January 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 530-540
The ACTION VAD registry: A collective five-year experience
- 5 February 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (7) , 602-608
Transcatheter Axial Pump Use in Pediatric Patients on Veno-Arterial Extracorporeal Membrane Oxygenation: An ACTION Collaborative Experience
We report the largest pediatric multicenter experience with Impella pump use and peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. Utilizing the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) collaborative database, we conducted a retrospective, multicenter study of all patients with cardiogenic shock requiring VA-ECMO support with subsequent Impella implant between October 2014 and December 2021. The primary outcome was defined as death while on Impella support. Secondary outcomes were recovery, transplantation, and transition to durable ventricular assist device (VAD) at the time of Impella explantation. Adverse events were defined according to the ACTION registry criteria. Twenty subjects were supported with Impella; Impella 2.5 (n = 3), CP (n = 12), 5.0/5.5 (n = 5). The median Interquartile range (IQR) age, weight, and body surface area at implantation were 15.6 years (IQR = 13.9–17.2), 65.7 kg (IQR = 53.1–80.7), and 1.74 m2 (IQR = 1.58–1.98). Primary cardiac diagnoses were dilated cardiomyopathy/myocarditis in nine (45%), congenital heart disease in four (20%), graft failure/rejection in four (20%), and three (15%) others. Most common adverse events included hemolysis (50%) and bleeding (20%). There were two deaths (10%) in the cohort. Nine patients (45%) were explanted for recovery, eight (40%) were transitioned to a durable VAD, and one (5%) underwent heart transplantation. Impella percutaneous pump support should be considered in the older pediatric population supported with peripheral VA-ECMO, as a means of left heart decompression, and a strategy to come off ECMO to achieve endpoints of myocardial recovery, transition to a durable VAD, or transplantation.
- 5 February 2024
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 70 (7) , 602-608
Transcatheter Axial Pump Use in Pediatric Patients on Veno-Arterial Extracorporeal Membrane Oxygenation: An ACTION Collaborative Experience
We report the largest pediatric multicenter experience with Impella pump use and peripheral veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support. Utilizing the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) collaborative database, we conducted a retrospective, multicenter study of all patients with cardiogenic shock requiring VA-ECMO support with subsequent Impella implant between October 2014 and December 2021. The primary outcome was defined as death while on Impella support. Secondary outcomes were recovery, transplantation, and transition to durable ventricular assist device (VAD) at the time of Impella explantation. Adverse events were defined according to the ACTION registry criteria. Twenty subjects were supported with Impella; Impella 2.5 (n = 3), CP (n = 12), 5.0/5.5 (n = 5). The median Interquartile range (IQR) age, weight, and body surface area at implantation were 15.6 years (IQR = 13.9–17.2), 65.7 kg (IQR = 53.1–80.7), and 1.74 m2 (IQR = 1.58–1.98). Primary cardiac diagnoses were dilated cardiomyopathy/myocarditis in nine (45%), congenital heart disease in four (20%), graft failure/rejection in four (20%), and three (15%) others. Most common adverse events included hemolysis (50%) and bleeding (20%). There were two deaths (10%) in the cohort. Nine patients (45%) were explanted for recovery, eight (40%) were transitioned to a durable VAD, and one (5%) underwent heart transplantation. Impella percutaneous pump support should be considered in the older pediatric population supported with peripheral VA-ECMO, as a means of left heart decompression, and a strategy to come off ECMO to achieve endpoints of myocardial recovery, transition to a durable VAD, or transplantation.
- 5 March 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (3) , e13990
Right heart failure considerations in pediatric ventricular assist devices
Right heart failure (RHF) is a vexing problem in children after left ventricular assist device (LVAD) implantation that can negatively impact transplant candidacy and survival. Anticipation, prevention, early identification and appropriate medical and device management of RHF are important to successful LVAD outcomes. However, there is limited pediatric evidence to guide practice. This pediatric‐focused review summarizes the relevant literature and describes the harmonized approach to RHF from the Advanced Cardiac Therapies Improving Outcomes Network (ACTION). This review seeks to improve RHF outcomes through the sharing of best practices and experience across the pediatric VAD community.
- 5 March 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (3) , e13990
Right heart failure considerations in pediatric ventricular assist devices
Right heart failure (RHF) is a vexing problem in children after left ventricular assist device (LVAD) implantation that can negatively impact transplant candidacy and survival. Anticipation, prevention, early identification and appropriate medical and device management of RHF are important to successful LVAD outcomes. However, there is limited pediatric evidence to guide practice. This pediatric‐focused review summarizes the relevant literature and describes the harmonized approach to RHF from the Advanced Cardiac Therapies Improving Outcomes Network (ACTION). This review seeks to improve RHF outcomes through the sharing of best practices and experience across the pediatric VAD community.
- 1 August 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (8) , 1103-1111
Eosinophil count, allergies, and rejection in pediatric heart transplant recipients
- 1 August 2015
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 34 (8) , 1103-1111
Eosinophil count, allergies, and rejection in pediatric heart transplant recipients